Q1 Earnings Forecast for VRDN Issued By Wedbush

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Research analysts at Wedbush issued their Q1 2026 earnings estimates for Viridian Therapeutics in a note issued to investors on Tuesday, November 12th. Wedbush analyst L. Chico expects that the company will post earnings per share of ($1.17) for the quarter. Wedbush has a “Outperform” rating and a $42.00 price target on the stock. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($3.94) per share. Wedbush also issued estimates for Viridian Therapeutics’ Q2 2026 earnings at ($1.21) EPS, Q3 2026 earnings at ($1.16) EPS and FY2028 earnings at $9.52 EPS.

VRDN has been the subject of several other research reports. BTIG Research increased their price objective on shares of Viridian Therapeutics from $56.00 to $61.00 and gave the company a “buy” rating in a research report on Thursday, September 26th. HC Wainwright lifted their price target on Viridian Therapeutics from $27.00 to $34.00 and gave the stock a “buy” rating in a research report on Thursday. Oppenheimer restated an “outperform” rating and set a $28.00 price objective (down from $31.00) on shares of Viridian Therapeutics in a research report on Monday, August 12th. Needham & Company LLC reiterated a “buy” rating and issued a $38.00 target price on shares of Viridian Therapeutics in a report on Wednesday. Finally, Royal Bank of Canada restated an “outperform” rating and set a $44.00 price target on shares of Viridian Therapeutics in a report on Thursday, September 19th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, Viridian Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $36.33.

Viridian Therapeutics Stock Performance

NASDAQ:VRDN opened at $20.14 on Thursday. The company has a market cap of $1.60 billion, a price-to-earnings ratio of -4.67 and a beta of 1.10. Viridian Therapeutics has a 1 year low of $11.40 and a 1 year high of $27.20. The stock’s 50 day simple moving average is $22.64 and its two-hundred day simple moving average is $16.97. The company has a debt-to-equity ratio of 0.05, a current ratio of 15.82 and a quick ratio of 15.82.

Insider Buying and Selling at Viridian Therapeutics

In related news, COO Thomas W. Beetham bought 5,000 shares of the stock in a transaction on Friday, September 27th. The stock was bought at an average price of $23.41 per share, for a total transaction of $117,050.00. Following the completion of the acquisition, the chief operating officer now directly owns 6,000 shares in the company, valued at approximately $140,460. This represents a 500.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Fairmount Funds Management Llc acquired 1,600,000 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The shares were bought at an average price of $18.75 per share, with a total value of $30,000,000.00. Following the completion of the purchase, the director now directly owns 3,445,813 shares in the company, valued at $64,608,993.75. The trade was a 86.68 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 1,626,400 shares of company stock valued at $30,616,312 in the last ninety days. Corporate insiders own 0.65% of the company’s stock.

Institutional Trading of Viridian Therapeutics

A number of institutional investors have recently made changes to their positions in the business. FMR LLC increased its stake in Viridian Therapeutics by 16.8% during the 3rd quarter. FMR LLC now owns 11,183,478 shares of the company’s stock valued at $254,424,000 after purchasing an additional 1,610,130 shares in the last quarter. Maverick Capital Ltd. raised its stake in shares of Viridian Therapeutics by 22.9% in the second quarter. Maverick Capital Ltd. now owns 3,307,945 shares of the company’s stock worth $43,036,000 after purchasing an additional 615,531 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Viridian Therapeutics by 7.8% during the first quarter. Vanguard Group Inc. now owns 3,234,279 shares of the company’s stock worth $56,632,000 after purchasing an additional 233,331 shares during the period. Novo Holdings A S increased its holdings in Viridian Therapeutics by 19.3% in the 3rd quarter. Novo Holdings A S now owns 2,385,000 shares of the company’s stock worth $54,259,000 after buying an additional 385,000 shares during the period. Finally, Great Point Partners LLC raised its position in Viridian Therapeutics by 50.0% during the 3rd quarter. Great Point Partners LLC now owns 750,000 shares of the company’s stock worth $17,062,000 after buying an additional 250,000 shares during the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.